Journal of clinical lipidology · 2026
Lipoprotein (a) variability in high cardiovascular risk individuals with hypertriglyceridemia and controlled LDL-C on statin therapy in REDUCE-IT.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Szarek Michael, Bhatt Deepak L, Miller Michael, Brinton Eliot A, Tardif Jean-Claude, Ballantyne Christie M, Ketchum Steven B, Lira Pineda Armando, Steg Ph Gabriel, Jacobson Terry A, Mason R Preston
Аннотация
BACKGROUND: Although repeated testing of lipoprotein(a) [Lp(a)] is generally not recommended because of the genetically determined nature of concentrations, reports of significant intraindividual variability in serial assessments have challenged the single lifetime measurement framework.
OBJECTIVE: To determine sources of Lp(a) variability among individuals with elevated triglyceride levels and well-controlled low-density lipoprotein cholesterol (LDL-C).
METHODS: Using Lp(a) assessments at baseline, month 12, and month 24 from participants in the Reduction of Cardiovascular Events with Icosapent Ethyl-Intervention Trial (REDUCE-IT), we identified characteristics that could support repeated testing.
RESULTS: Among 386 participants with baseline Lp(a) 50 to <70 mg/dL, 140 (36.3%) had at least 1 subsequent assessment ≥70 mg/dL, whereas among 630 participants with baseline Lp(a) ≥70 mg/dL, 133 (21.1%) had at least 1 subsequent assessment <70 mg/dL. Baseline Lp(a), sex (female vs male), race, and several other characteristics were related to variability.
CONCLUSION: Among individuals at high cardiovascular risk with hypertriglyceridemia and controlled LDL-C on statin therapy, considerable variability was observed over 24 months. These findings suggest multiple assessments may be warranted for Lp(a)-related risk stratification and, potentially, eligibility for Lp(a)-targeted treatments, particularly among individuals with relatively high concentrations or certain demographic and clinical characteristics.
OBJECTIVE: To determine sources of Lp(a) variability among individuals with elevated triglyceride levels and well-controlled low-density lipoprotein cholesterol (LDL-C).
METHODS: Using Lp(a) assessments at baseline, month 12, and month 24 from participants in the Reduction of Cardiovascular Events with Icosapent Ethyl-Intervention Trial (REDUCE-IT), we identified characteristics that could support repeated testing.
RESULTS: Among 386 participants with baseline Lp(a) 50 to <70 mg/dL, 140 (36.3%) had at least 1 subsequent assessment ≥70 mg/dL, whereas among 630 participants with baseline Lp(a) ≥70 mg/dL, 133 (21.1%) had at least 1 subsequent assessment <70 mg/dL. Baseline Lp(a), sex (female vs male), race, and several other characteristics were related to variability.
CONCLUSION: Among individuals at high cardiovascular risk with hypertriglyceridemia and controlled LDL-C on statin therapy, considerable variability was observed over 24 months. These findings suggest multiple assessments may be warranted for Lp(a)-related risk stratification and, potentially, eligibility for Lp(a)-targeted treatments, particularly among individuals with relatively high concentrations or certain demographic and clinical characteristics.